Literature DB >> 9435423

Hormonal effects of flutamide in young women with polycystic ovary syndrome.

V De Leo1, D Lanzetta, D D'Antona, A la Marca, G Morgante.   

Abstract

Anovulation in women with polycystic ovary syndrome (PCOS) is the direct effect of high local androgen concentrations on the ovary. Antiandrogens are substances that prevent androgens from expressing their activity on target tissues. Flutamide is a nonsteroid antiandrogen that has been found effective in hirsute patients, although its mechanism of action is unclear. Eight girls, ranging in age from 16-19 yr, with moderate to severe hirsutism and menstrual irregularities were enrolled in this study. The basal hormonal pattern showed anovulatory cycles; increased concentrations of LH, androstenedione, and testosterone; and increased LH/FSH ratio. A baseline ultrasound scan revealed polycystic ovaries in all patients. All were given 250 mg flutamide twice a day for 6 months. LH, FSH, androstenedione, testosterone, estradiol, and progesterone were evaluated before treatment, every 4 days during the third month of treatment, and on day 24 of the sixth month of treatment. Hirsutism improved, androgen levels dropped, and ovulatory cycles were restored in all subjects. Ultrasonographic examination in follicular phase showed a significant reduction in ovarian volume and ovaries of normal appearance with one dominant follicle. The most important result of the present study was that flutamide restored ovulation in anovulatory PCOS patients. This finding supports the hypothesis that flutamide reduces androgen synthesis through restoration of ovulation, although a direct block of the steroidogenic enzymes of androgen biosynthesis in ovarian thecal cells cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9435423     DOI: 10.1210/jcem.83.1.4500

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  Developmental programming: prenatal and postnatal contribution of androgens and insulin in the reprogramming of estradiol positive feedback disruptions in prenatal testosterone-treated sheep.

Authors:  Bachir Abi Salloum; Carol Herkimer; James S Lee; Almudena Veiga-Lopez; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2012-03-27       Impact factor: 4.736

Review 2.  Neuroendocrine dysfunction in PCOS: a critique of recent reviews.

Authors:  Suhail A R Doi
Journal:  Clin Med Res       Date:  2008-09

3.  Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome.

Authors:  S A R Doi; M Al-Zaid; P A Towers; C J Scott; K A S Al-Shoumer
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

4.  Ovarian Androgens Maintain High GnRH Neuron Firing Rate in Adult Prenatally-Androgenized Female Mice.

Authors:  Eden A Dulka; Laura L Burger; Suzanne M Moenter
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

Review 5.  How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

Authors:  E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 6.  New routes in the polycystic ovary syndrome labyrinth: a way out?

Authors:  P Moghetti; R Castello
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 7.  Polycystic ovary syndrome: What is it? Pathogenetic enigma and therapeutic dilemma.

Authors:  V Toscano
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 8.  Estrogen-progestagen therapy in the management of the polycystic ovary syndrome.

Authors:  J C Marshall
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

9.  PCOS: Animal models for PCOS - not the real thing.

Authors:  Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2017-05-05       Impact factor: 43.330

Review 10.  Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.

Authors:  David H Abbott; Daniel A Dumesic; Jon E Levine
Journal:  Expert Rev Endocrinol Metab       Date:  2019-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.